Menu
Menu
🌍 We’re proud to highlight that Tyrolpath, the largest private pathology lab in western Austria, is the first lab in Austria to adopt MSK-IMPACT®-Flex powered with SOPHiA DDM™, marking a major milestone for precision oncology in the country.
With approximately 45,000 new cancer diagnoses reported each year, there is a strong need for comprehensive genomic profiling (CGP) to identify actionable mutations, especially as precision oncology becomes more central in clinical practice.
“I have met with the experts at Memorial Sloan Kettering Cancer Center before, and having the opportunity to utilize their assays in my own lab thanks to SOPHiA GENETICS is going to be a transformative step for cancer testing in Austria. Leveraging the power of the SOPHiA DDM™ Platform will help us advance precision oncology for our Austrian patients.” Said Peter Obrist, CEO, Tyrolpath.
Built on the proven backbone of MSK-IMPACT® combined with the cloud-based SOPHiA DDM™ Platform, MSK-IMPACT® Flex empowers laboratories to achieve flexible, cost-efficient insights into key solid tumor biomarkers based on individual patient cases.
🧬 At SOPHiA GENETICS, we believe in empowering labs to accelerate innovation. With this collaboration, we’re taking another step forward in bringing cutting-edge CGP testing to Austria.
Learn more about our comprehensive genomic profiling applications: https://sophiastg.wpenginepowered.com/sophia-ddm-for-genomics/solid-tumors/cgp/
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
